Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis. Shigellosis i ...